CTXR   $0.39  -4.88% Market Closed After Close 0.3999 2.54%

Citius Pharmaceuticals Inc
Last Events:

2023-08-09 Trend pattern changed from сужающийся канал to расширяющийся канал.

2023-08-09 Signal in Stochastic changed from bearish recovery to bearish weakening. The stochastic indicator is in the lower part of the neutral territory and it grows. These factors indicate that the upside trend is confirmed. Last signal: main and signal line crossing.

2023-08-09 Signal in RSI changed from bearish recovery to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: exit from the overbought zone.

2023-08-06 Signal in RSI changed from bullish reversal to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-06 Trend Power changed from almost flat to .

2023-08-06 Trend changed from linear up to up and flat.

2023-08-05 Signal in RSI changed from bearish recovery to bullish reversal. RSI indicator is in the lower part of the neutral territory and left the oversold territory. These factors indicate that perhaps the downside trend is coming to an end price will probably head north Last signal: exit from the overbought zone.

2023-08-05 Trend Power changed from slow to almost flat.


Current temperature: 6.71
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 3
Target Price Mean 4.67
Mean unverified/preliminary 4.67 / 4.67
Target Price Low / High 4.00 / 6.00
Median / STD DEV 4.00 / 1.15
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total None ActivelyBuy ActivelyBuy
rsi Sell ActivelyBuy ActivelyBuy
macd None None None
stoch None None None
ma20 ActivelyBuy Buy None
ma50 None None None
ma100 None Buy None
Candlestick PatternOct. 9, 2024 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN US17322U2078
ceo Mr. Leonard L. Mazur
Website https://citiuspharma.com
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. The Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido completed. The company was founded in 2007 and is headquartered in Cranford, New Jersey.